Get started
Author

Marco Nievo

Observed name: Nievo, Marco
Observed institution: Children's Tumor Foundation
ORCID: 0000-0001-6700-4768
Observed ORCID: 0000-0001-6700-4768
OpenAlex ID: A5086942088
Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL
2023 · Franz Koenig, Cécile Spiertz, et al. · EClinicalMedicine · 61
PDF
Identifying challenges in neurofibromatosis: a modified Delphi procedure
2021 · Britt A. E. Dhaenens, Rosalie E. Ferner, et al. · European Journal of Human Genetics · 14
PDF
Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases
2024 · Britt A E Dhaenens, Günter Heimann, et al. · Neuro-Oncology Practice · 9
PDF
Neurofibromatosis as a gateway to better treatment for a variety of malignancies
2016 · Annette C. Bakker, Salvatore La Rosa, et al. · Progress in Neurobiology · 9
Lessons learned from drug trials in neurofibromatosis: A systematic review
2021 · Britt A.E. Dhaenens, Rosalie E. Ferner, et al. · European Journal of Medical Genetics · 5
PDF
A basket-platform trial for neurofibromatosis type 1: A potential model for rare cancer predisposition syndromes.
2023 · Annette Bakker, Britt Dhaenens, et al. · Journal of Clinical Oncology · 1
PDF
Abstract 4643: Drug-Target Explorer: An interactive tool for examining chemical-biological interactions
2018 · Robert J. Allaway, Sara J. Gosline, et al. · Cancer Research
2018 AACR Drug Target Explorer
2018 · Allaway, Robert, Gosline, Sara, et al. · Figshare
Works count: 8
Citation count: 99
H-index: 5
I10-index: 2
Year
Topic
Type